With a new No. 1, Avrobio hopes to get investors back on gene therapy bandwagon

It’s been a year since Avrobio suffered a blow to its gene therapy ambitions with the failure of a Fabry disease program. Now, the biotech is ready to reintroduce itself to investors with a small positive data set for its new No. 1 priority and the go-ahead from the FDA to advance the clinical program in a rare disease.